Head and neck squamous cell carcinoma
Conditions
Interventions
experimental group:Carrilizumab+ Platinum chemotherapy + radiotherapy
control group:Platinum chemotherapy + radiotherapy
Sponsors
West District of the First Affiliated Hospital of University of Science and Technology of China
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Subjects aged 18-75 years, male or female; 2. Patients with stage III and IV head and neck squamous cell carcinoma confirmed by pathology or histology; 3. Patients with at least one measurable lesion (spiral CT scan >= 10 mm, meeting RECIST 1.1 standard); 4. Patients who have not received radical radiotherapy (except neoadjuvant therapy) or concurrent chemoradiotherapy, immunotherapy or targeted therapy; 5. Patients with indications for treatment; 6. ECoG score: 0-1; 7. Patients whose expected survival time is more than or equal to 3 months; 8. Patients with normal function of main organs meet the following criteria: (1) The standard of blood routine examination should be met (no blood transfusion or blood products within 14 days) HB >= 90 g/L ANC >= 1.5 * 10^9/L PLT >= 80 * 10^9/L (2) Biochemical tests should meet the following standards: TBIL 45 ml / min (Cockcroft Gault formula); 9. The patients who volunteered to join the study signed the informed consent, with good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with severe uncontrollable infection; 2. Pregnant or lactating women; 3. Patients with known hereditary or acquired bleeding and thrombotic tendency (such as hemophilia, coagulation dysfunction, thrombocytopenia, etc.); 4. Other conditions considered by the researcher not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR;DCR;OS;PFS;AE; | — |
Countries
China
Contacts
Public ContactJin Gao
West District of the First Affiliated Hospital of University of Science and Technology of China
Outcome results
None listed